Population pharmacokinetics I: background, concepts, and models. - Wikidata - awgldk - TriplyDB

Population pharmacokinetics I: background, concepts, and models.

Population pharmacokinetics I: background, concepts, and models.

http://www.wikidata.org/entity/Q35870696

about

A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment Covariate pharmacokinetic model building in oncology and its potential clinical relevance.Understanding and applying pharmacometric modelling and simulation in clinical practice and research Estimation of pharmacokinetic parameters based on the patient-adjusted population data.Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding Population pharmacokinetics II: estimation methods.Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients.Clinical trials in pediatric traumatic brain injury: unique challenges and potential responses.Manual blood exchange transfusion does not significantly contribute to parasite clearance in artesunate-treated individuals with imported severe Plasmodium falciparum malaria External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.Understanding the time course of pharmacological effect: a PKPD approach.Fundamentals of population pharmacokinetic modelling: modelling and software.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Population pharmacokinetics of cyclosporine in transplant recipients.Population pharmacometrics in support of analgesics studies.Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software.Pharmacokinetics and pharmacodynamics of dexmedetomidine.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.A Population Pharmacokinetic Analysis of Fimasartan, a Selective Angiotensin II Receptor Antagonist, in Healthy Caucasian Subjects and Korean Patients With Hypertension.Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models Chain length of dietary alkylresorcinols affects their in vivo elimination kinetics in rats.Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics.

P2860

Q26862558-2F9663C9-9DDB-4F25-B82F-2427582B9BE0 Q27687599-D5639644-084F-4214-A64A-ADA04D790D80 Q28468334-95ECBDA9-7583-400E-B807-92F9B9C12C71 Q31082856-F5C803B9-F1C2-4C7F-9490-E8245BA03696 Q31147438-88E9E84C-35D3-4AC1-B0F2-C300813EEB37 Q33571417-8E4F5760-1935-4FB9-A212-03A7EAF55886 Q33827819-10CB91DF-1F99-44CB-BF07-0D0ED9E7D4A3 Q34996894-FEAE5286-26D4-42C3-B5E6-5465D1E4EF3C Q35544621-8DC12B06-EAE6-40E4-8F4D-8A80AF854324 Q35887615-38840D64-1AF5-4B46-9936-45C4F287E117 Q35928858-AF75C975-9BF7-46EB-99D3-93B5388A8CEF Q35972218-D0560500-D737-4F73-8E59-C350389E570E Q36545066-9628F729-262C-449F-A1E2-E0B86DAC44E1 Q36582084-80D497A0-F01C-4BE9-833B-3DBEED440C81 Q36741273-6982A3CD-B83B-4D5A-BB98-63208EBB2632 Q36806621-673379F6-C38C-43AB-99D6-D84877F0BF58 Q37237006-9AB8FAC2-8358-45F5-B357-BA719993F764 Q37298637-F7B0F105-4194-4943-AB2B-64DA8C0E7FEF Q37298794-0A1B7E13-BA5D-49BE-9B76-DC4BDF37711E Q37832754-D18A0615-C88C-4E0B-81CA-D37859FFCE64 Q38016955-B7A05FE5-8B52-41F3-9CAA-B2B77CF9696D Q38103885-7E827DD5-8C21-4B48-B8F2-F601F9AFC94B Q38115174-580E21B7-465F-49D5-A1DA-6D315BC04968 Q38175171-D1F0F0EF-B799-498D-AF7F-D2E31FBCA062 Q38233301-41D6CDE6-2207-4DD1-87DD-36790166A540 Q38258649-AFC74C58-5B1C-4326-AAD8-4451F44AF821 Q38930366-7D554746-F91D-4EA4-86F0-4BFE60E91A10 Q38946488-89A161E2-2FEE-454E-A53D-1F2D5FA107B8 Q39475869-496D2522-245A-4EA8-B77D-0E408B21DEFE Q39602527-E7E8FECE-206A-4546-BBDD-476FC5929A6A Q39816357-1C017AE2-EFF5-4DA7-A90B-C08560E9CFED Q39956407-69CBC098-B760-482D-AEA5-46FE05A5368A Q40749709-BED94328-6454-4C97-A7F1-18EE4B5810DE Q41819996-7A742E38-A266-4C4B-BDD6-CCB732CA11DB Q42218978-9C376E40-C3B2-4097-AFDB-B7B6567EB828 Q43451894-D71A52E2-980F-43A2-B710-E5B93D9C8286 Q43984406-AAD45BC9-B8BF-4A19-8FFB-96B5D1C95197 Q44796146-FE256534-8522-440A-8D67-22106964EF7F Q45869569-F64EBF76-C8A6-4B43-86DB-F5405234FB05 Q46244052-30000269-A1EE-418F-A96F-5E59E6DA0984

P2860

Population pharmacokinetics I: background, concepts, and models.

http://www.wikidata.org/entity/Q35870696

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Population pharmacokinetics I: background, concepts, and models.

@ast

Population pharmacokinetics I: background, concepts, and models.

@en

type

label

Population pharmacokinetics I: background, concepts, and models.

@ast

Population pharmacokinetics I: background, concepts, and models.

@en

prefLabel

Population pharmacokinetics I: background, concepts, and models.

@ast

Population pharmacokinetics I: background, concepts, and models.

@en

P1433

Q35870696-176ADD0A-11DB-46A4-81FC-F1997A8C1E24

P1476

Q35870696-380A25F1-43AB-477F-9317-47D3B6C82B37

P2093

Q35870696-0300DCE5-3B70-4962-BACA-72C00BDFBEB1

Q35870696-52752D9B-6D60-4E33-8763-FC67EC275A39

P2860

Q35870696-108CE59A-EAE3-4019-8EBA-F8A4FDF04215

Q35870696-1B1FAE8B-41CC-406A-880C-733D7E866AD4

Q35870696-1EF78DC7-216E-44E1-B839-1789A7C35B5C

Q35870696-1F9C1A4A-456B-4574-8B0F-311676827517

Q35870696-25FDC754-8A4A-49E3-82AC-ED7EA47C2B05

Q35870696-943157A5-A7B3-4C2C-AA53-6B212F112AE6

Q35870696-ABBB0F62-CBAA-4CED-97AA-290A1D69CDC2

Q35870696-B948B8C7-EBA0-4AEF-B7BA-718404313FB1

Q35870696-D8635204-AD66-4A7D-9060-EDC5959B8C3F

Q35870696-E65BE7A4-01BD-4F58-8FAC-F15D3CC6C0A8

P304

Q35870696-97758052-0D51-45C7-B039-26A515033C9C

P31

Q35870696-396A7725-D4ED-4C24-B673-3B0103487815

P356

Q35870696-C82C317C-EA57-40AA-95E2-D4638EAE6411

P407

Q35870696-827A50A6-E03C-4467-B452-32C6BB44D65C

P433

Q35870696-349BE439-979A-4C9D-8002-125E2A7B63FA

P478

Q35870696-CB0211FB-1C50-44D9-BE7A-E18AD1F8A89D

P577

Q35870696-4BDA93EB-6526-48A5-940E-0285A52D6967

P5875

Q35870696-9BA1E9B1-5FB2-490E-A804-302D4B4B3946

P698

Q35870696-BBC09AA5-29AD-48F5-A69B-C113DE3821C3

P356

P1433

Annals of Pharmacotherapy

P1476

Population pharmacokinetics I: background, concepts, and models.

@en

P2093

Ene I Ette

http://www.w3.org/2001/XMLSchema#string

Paul J Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Forecasting individual pharmacokinetics

Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.

Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Population pharmacokinetics. Theory and clinical application.

Pharmacokinetic studies in elderly people. Are they necessary?

Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

P304

1702-1706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1D374

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8384560

http://www.w3.org/2001/XMLSchema#string

P698

15328391

http://www.w3.org/2001/XMLSchema#string